Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients

Inclusion Criteria: Both HIV infected and HIV uninfected individuals are eligible for this study. CD4 cell count of 400 cells/mm3 or greater at study entry If HIV infected, initiated anti-HIV medicines within 120 days of infection If HIV infected, HIV viral load < 50 copies/ml for at least 3 months prior to study entry Current medication regimen for at least 3 months prior to study entry A particular blood type (HLA-A*0201) Acceptable methods of contraception Exclusion Criteria: Received investigational drug or vaccine within 30 days prior to study entry On other immune-based therapy (e.g., interleukin-2, alpha interferon, immunoglobulin, thalidomide) within 30 days prior to study entry Megesterol acetate within 30 days prior to study entry Immunization within 4 weeks of study entry If hepatitis B virus (HBV) uninfected and at high risk for HBV infection, the patient will not be eligible until he or she has completed an HBV vaccine series. Unstable or severe medical condition, including active opportunistic infection requiring treatment History of Hashimoto's thyroiditis Cancer requiring chemotherapy within 6 months prior to study entry History of radiation therapy to axillary lymph nodes Significant laboratory abnormalities at study entry Pregnant or breastfeeding History of autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, autoimmune hepatitis, scleroderma, mixed connective tissue disorder) Allergy to gentamicin, tobramycin, streptomycin, or amikacin